Chemily Revenue and Competitors
Estimated Revenue & Valuation
- Chemily's estimated annual revenue is currently $620k per year.
- Chemily's estimated revenue per employee is $155,000
Employee Data
- Chemily has 4 Employees.
- Chemily grew their employee count by -33% last year.
Chemily's People
Name | Title | Email/Phone |
---|
Chemily Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $1.7M | 11 | -8% | N/A | N/A |
#3 | $2.3M | 15 | 50% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $17.1M | 110 | 5% | $0.07B | N/A |
#6 | $4M | 26 | -7% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $1.1M | 7 | 17% | N/A | N/A |
#9 | $7.8M | 50 | 2% | N/A | N/A |
#10 | $1.7M | 11 | 10% | N/A | N/A |
What Is Chemily?
Chemily, LLC is a research, development and consulting company focusing on cost-effective synthesis of glycan libraries, carbohydrate-based biochemicals, reagents and pharmaceuticals. CHEMILY is aiming at developing into a major supplier for carbohydrate-based biochemicals, reagents and pharmaceuticals, and has been manufacturing several categories of products using it's proprietary chemo-enzymatic and in vivo bioengineering technology. Some of the new developments include: 1.Structure-defined oligosaccharides and glycolipids; 2.Immunogenic bacterial cell surface polysaccharides; 3.Sugar nucleotides and their derivatives; 4.Carbohydrate-based pharmaceuticals and glycoprotein vaccines; 5.Carbohydrate related enzymes, such as glycosyl transferases, glycosyl hydrolases, sugar nucleotide biosynthesized enzymes. Based on its proprietary carbohydrate and uncommon sugar library (deposits), CHEMILY has been developing sugar-containing small molecules in therapeutic treatment options in two core disease areas: cancer and cardiovascular diseases. Recently, CHEMILY has been licensing and developing novel glycoconjugation technology in order to produce polysaccharide-protein conjugate vaccines and therapeutic glycoproteins to unprecedented cost effective levels.
keywords:N/AN/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 4 | N/A | N/A |
#2 | $0.3M | 4 | N/A | N/A |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.3M | 4 | N/A | N/A |